Management of patients with polycythaemia vera: Results of a survey among Swedish haematologists

European Journal of Haematology

Volumn 74, Issue 6, 2005, Pages 489-495

  Andreasson, Björn ^a   Lökenberg, Eva ^b   Westin, Jan ^c,d  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d LUND UNIVERSITY   (Sweden)

Author keywords

Diagnosis; Management; Polycythaemia vera; Therapy

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANAGRELIDE; BUSULFAN; COBALAMIN; ERYTHROPOIETIN; HYDROXYUREA; PHOSPHORUS 32;

ARTERIAL OXYGEN SATURATION; BONE MARROW EXAMINATION; CLINICAL PRACTICE; DIAGNOSTIC PROCEDURE; DRUG PREFERENCE; ERYTHROCYTE; HEALTH SURVEY; HISTOPATHOLOGY; HUMAN; MEDICAL SPECIALIST; PHLEBOTOMY; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROPHYLAXIS; QUESTIONNAIRE; REVIEW; SPLEEN SIZE; SWEDEN; TREATMENT OUTCOME;

EID: 18844436219     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2005.00424.x     Document Type: Review

References (20)

1. Grupp Italiano Studio Policitemia. Polycythemia Vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med 1995;123:656-664.
2. BERLIN NI. Diagnosis and classification of the polycythemias. Semin Hematol 1975;12:339-351.
3. PEARSON TC, MESSINEZY M. The diagnostic criteria of polycythaemia rubra vera. Leuk Lymphoma 1996;22(Suppl 1):87-93.
4. WHO. Pathology and genetics of tumours of hematopoietic and lymphoid tissues. In: JAFFE ES, HARRIS NL, STEIN H, VARDIMAN JW, eds. World Health Organization Classification of Tumours. Lyon: IARC Press, 2001:20-41.
5. BIRGEGÅRD G, BJÖRKHOLM M, KUTTI J, LÖFVENBERG E, SAMUELSSON J, WESTIN J. Polycytemia vera, essentiell trombocytemi och myelofibros. Diagnostik, behandling och uppföljning. Rekommendationer från en nationell arbetsgrupp (Polycythaemia vera, essential thrombocythaemia and myelofibrosis. Recommendations from a national working party). Stockholm 1998.
6. STREIFF MB, SMITH B, SPIVAK JL. The diagnosis and management of polycythemia vera in the era since the polycythemia vera study group: a survey of American society of hematology members' practice patterns. Blood 2002;99:1144-1149.
7. JOHANSSON P, ANDREASSON B, SAFAI-KUTTI S, RHEDIN C, VILEN L, VÄÄRT J, KUTTI J. On the diagnosis of polycythemia vera as assessed in the health and medical care in the Västra Götaland Region, Sweden. J Int Med 2002;251:1-7.
8. WASSERMAN L. The management of polycythemia vera. Br J Haematol 1971;21:371-376.
9. LUNDIN PM, RIDELL B, WEINFELD A. The significance of bone marrow morphology for the diagnosis of polycythaemia vera. Scand J Haematol 1972;9:271-282.
10. COTES PM, DORE CJ, YIN JA, LEWIS SM, MESSINEZY M, PEARSON TC, REID C. Determination of serum immunoreactive erythropoietin in the investigation of erythrocytosis. N Engl J Med 1986;315:283-287.
11. BIRGEGÅRD G, WIDE L. Serum erythropoietin in the diagnosis of polycythaemia and after phlebotomy treatment. Br J Haematol 1992;81:603-606.
12. MOSSUZ P, GIRODON F, DONNARD M, LATGER-CANNARD V, DOBO I, BOIRET N, LECRON JC, BINQUET C, BARRO C, HERMOUET S, PRALORAN V. Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. Haematologica 2004;89:1194-1198.
13. LINDSTEDT G, LUNDBERG PA. Are current methods of measurement of erythropoietin (EPO) human plasma or serum adequate for the diagnosis of polycythaemia vera and the assessment of EPO deficiency? Scand J Clin Lab Invest 1998;58:441-458.
14. TEFFERI A. Diagnosing polycythemia vera: a paradigm shift. Mayo Clin Proc 1999;74:159-162.
15. BRANDT L, ANDERSSON H. Survival and risk of leukaemia in polycythaemia vera and essential thrombocythaemia treated with oral radiophosphorus: are safer drugs available? Eur J Haematol 1995;54:21-26.
16. GREEN AR, VASSILIOU GS, CURTIN N, CAMPBELL PJ. Management of the myeloproliferative disorders: distinguishing data from dogma. Haematol J 2004;5:S126-S132.
17. LANDOLFI R, MARCHIOLI R, KUTTI J, GISSLINGER H, TOGNONI G, PATRONO C, BARBUI T. European collaboration on low-dose aspirin in polycythaemia vera. N Engl J Med 2004;350:114-124.
18. PEARSON TC, WETHERLEY-MEIN G. Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet 1978;2:1219-1222.
19. SPIVAK JL. The optimal management of polycythaemia vera. Br J Haematol 2002;116:243-254.
20. MICHIELS JJ, THIELE J. Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera and idiopathic myelofibrosis (agnogenic myeloid metaplasia). Int J Haematol 2002;76:133-145.